| Code | Description | Claims | Beneficiaries | Total Paid |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
233,304 |
221,426 |
$19.78M |
| S9083 |
Global fee urgent care centers |
183,821 |
164,812 |
$16.44M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
207,280 |
190,681 |
$13.04M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
55,790 |
54,210 |
$4.26M |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
101,465 |
95,807 |
$2.85M |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
107,807 |
102,670 |
$2.23M |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
150,815 |
73,667 |
$2.00M |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
12,899 |
12,507 |
$1.27M |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
34,618 |
32,408 |
$802K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
6,029 |
5,771 |
$451K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
24,320 |
22,326 |
$437K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
5,551 |
5,348 |
$431K |
| 81003 |
|
30,643 |
29,303 |
$286K |
| 71046 |
Radiologic examination, chest; 2 views |
11,989 |
11,322 |
$256K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
3,433 |
3,346 |
$177K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,479 |
4,287 |
$174K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,763 |
9,329 |
$127K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
1,355 |
1,310 |
$106K |
| 73610 |
|
4,713 |
4,423 |
$100K |
| 99215 |
Prolong outpt/office vis |
1,078 |
985 |
$100K |
| 73630 |
|
4,920 |
4,541 |
$99K |
| 81025 |
|
8,116 |
7,794 |
$98K |
| L4350 |
Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf |
1,779 |
1,680 |
$96K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
1,159 |
1,118 |
$83K |
| E0114 |
Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips |
2,845 |
2,729 |
$78K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
1,694 |
1,620 |
$69K |
| 73130 |
|
3,096 |
2,915 |
$68K |
| 73110 |
|
2,877 |
2,702 |
$68K |
| 73562 |
|
2,995 |
2,754 |
$66K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,202 |
6,703 |
$66K |
| A6449 |
Light compression bandage, elastic, knitted/woven, width greater than or equal to three inches and less than five inches, per yard |
6,456 |
6,040 |
$60K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,422 |
2,124 |
$60K |
| 99384 |
|
512 |
503 |
$45K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
3,451 |
3,237 |
$40K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
3,681 |
3,501 |
$39K |
| 12001 |
|
774 |
719 |
$38K |
| 10060 |
|
549 |
536 |
$37K |
| 73140 |
|
1,650 |
1,573 |
$35K |
| 99383 |
|
454 |
434 |
$34K |
| 74018 |
|
1,688 |
1,620 |
$34K |
| 93000 |
|
2,681 |
2,598 |
$34K |
| L3260 |
Surgical boot/shoe, each |
929 |
846 |
$33K |
| 73030 |
|
1,586 |
1,509 |
$33K |
| 74022 |
|
860 |
847 |
$30K |
| 72100 |
|
1,246 |
1,193 |
$28K |
| 99205 |
Prolong outpt/office vis |
242 |
228 |
$26K |
| 86308 |
|
2,162 |
2,082 |
$23K |
| 73080 |
|
1,141 |
1,079 |
$23K |
| A4565 |
Slings |
1,427 |
1,364 |
$21K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
3,257 |
2,875 |
$20K |
| 82947 |
|
2,124 |
2,038 |
$19K |
| 71101 |
|
786 |
759 |
$18K |
| 29125 |
|
438 |
423 |
$17K |
| 36415 |
Collection of venous blood by venipuncture |
2,421 |
2,220 |
$14K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
1,433 |
1,370 |
$13K |
| S0077 |
Injection, clindamycin phosphate, 300 mg |
600 |
587 |
$11K |
| Q4049 |
Finger splint, static |
901 |
867 |
$10K |
| 90714 |
|
1,308 |
1,166 |
$9K |
| 90674 |
|
1,316 |
1,159 |
$8K |
| 73090 |
|
347 |
316 |
$6K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
332 |
328 |
$5K |
| J7644 |
Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram |
374 |
368 |
$5K |
| 12002 |
|
80 |
69 |
$4K |
| 69209 |
|
454 |
413 |
$4K |
| 73590 |
|
237 |
204 |
$4K |
| 97802 |
|
307 |
287 |
$3K |
| Q4022 |
Cast supplies, short arm splint, adult (11 years +), fiberglass |
148 |
144 |
$3K |
| 73502 |
|
154 |
146 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
524 |
458 |
$2K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
445 |
374 |
$2K |
| 72040 |
|
70 |
70 |
$2K |
| 99201 |
|
31 |
31 |
$941.63 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
93 |
89 |
$771.98 |
| 29515 |
|
12 |
12 |
$366.06 |
| 90715 |
|
208 |
126 |
$355.42 |
| 73660 |
|
12 |
12 |
$164.93 |
| 90661 |
|
71 |
69 |
$100.98 |
| G0008 |
Administration of influenza virus vaccine |
20 |
19 |
$77.00 |
| Q4024 |
Cast supplies, short arm splint, pediatric (0-10 years), fiberglass |
12 |
12 |
$44.01 |
| 97803 |
|
77 |
50 |
$40.00 |
| S9088 |
Services provided in an urgent care center (list in addition to code for service) |
157 |
129 |
$17.00 |
| 87070 |
|
110 |
107 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
186 |
172 |
$0.00 |
| 99000 |
|
58 |
55 |
$0.00 |
| 99051 |
|
12 |
12 |
$0.00 |